Compare Atlassian Corporation PLC (TEAM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs BIO-TECHNE Corp — how do they compare? Atlassian Corporation PLC trades at $206.79 (market cap $51.53B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Atlassian Corporation PLC is far larger — about 4.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals — on Pluang, investors hold Atlassian Corporation PLC for 65 Days and BIO-TECHNE Corp for 64 Days on average.
| TEAM | TECH | |
|---|---|---|
Market Cap | $51.53B | $11.36B |
Volume | 2,904,511 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $206.79 | $72.61 |
52-Week Low | $57.15 | $43.31 |
Typical Hold Time | 65 Days | 64 Days |
Enterprise Value | $51.52B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $203.57, up 4.04% on the day, with a bullish technical signal from moving averages and strong analyst support. Revenue growth is robust, reaching $5.22B in 2025, though the company remains unprofitable with a net income margin of -0.82%. Recent news highlights AI-driven product adoption and cloud momentum as key growth catalysts, with the stock rallying 180% since April 2026 according to Investor's Business Daily on 2026-09-18.
The outlook is positive due to AI integration and market expansion, but high valuation multiples (P/S of 8.06, EV/EBITDA of 242.85) and persistent losses pose risks. Analysts are overwhelmingly bullish with a 69.77% buy rating and a consensus price target of $191.16, though the current price exceeds this target, suggesting near-term caution amid long-term growth potential.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, as the stock approaches its 52-week high of $72.70. The company shows strong profitability with 65.77% gross margins and 14.97% net income margin, though earnings have been mixed with one miss and two beats in recent quarters. Technical indicators show a bullish trend with support at $72 and resistance at $73. Recent news highlights shareholder approval of the Merck KGaA acquisition at $73 per share, providing a clear near-term catalyst.
The acquisition premium offers limited upside from current levels, while fundamental metrics show elevated valuation (P/E 62.46) despite solid profitability. Key risks include integration challenges post-acquisition and potential regulatory scrutiny. Analyst consensus leans neutral with 46% buy ratings and a $65.78 price target below current trading levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
